Navigation Links
ULURU Inc. Announces Conference Call
Date:11/8/2010

ADDISON, Texas, Nov. 8, 2010 /PRNewswire-FirstCall/ -- ULURU Inc. (NYSE Amex: ULU) today announced that it has scheduled a conference call to discuss the third quarter ended September 30, 2010 financial results and to provide a general business update on Friday, November 12, 2010 at 9:00 a.m. Eastern Time.

To participate in the conference call please dial (800) 357-0498, for international callers dial (850) 429-1388 (access code 23699#) five to ten minutes prior to the initiation of the teleconference. If you are unable to listen to the live broadcast, a replay of the call will be available starting on November 12, 2010 two hours following the end of the call until November 26, 2010 at 11:59 p.m. Eastern Time. For the U.S. replay, please dial (866) 415-9493 for international callers dial (585) 419-6446 (access code 23699#). You may also access the replay of the call two hours following the end of the call until November 26, 2010 at 11:59 p.m. Eastern Time via the web by logging onto http://app.replayrecorder.com/multipoint/.

About ULURU Inc.:ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers with improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex™ Aggregate technology and OraDisc™ transmucosal delivery system. For more information about ULURU Inc., please visit www.uluruinc.com. For more information about Altrazeal™, please visit www.Altrazeal.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended. These statements are subject to numerous risks and unc
'/>"/>

SOURCE ULURU Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. ULURU Inc. Reports Second Quarter 2010 Financial Results
2. ULURU Inc. Invited to Present Altrazeal(TM) Research at 10th Annual Wound Healing Science and Industry Conference
3. ULURU Inc. Obtains Status of Approved Supplier With McKesson.
4. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2009 and to Provide a Business Update
5. ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009
6. ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
7. TechniScan, Inc. Announces Restructuring of Convertible Debt
8. Mederi Therapeutics Announces Receipt of CE Mark for its Second Generation Secca® and Stretta® Systems
9. Biotel, Inc. Announces Definitive Merger Agreement With CardioNet, Inc.
10. Fuisz Announces Issuance of Patent for the New Generation of Glucose and Other Analyte Analyzers
11. ShangPharma Announces Appointment of Benson Tsang as a Member of the Board of Directors and Audit Committee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014 Nanomix Inc., (Nanomix), a ... of mobile diagnostic tests to enable earlier ... pre-hospital settings, today announced it has received ... certification was awarded by the British Standards ... certification bodies. ISO 13485:2003 ...
(Date:11/26/2014)... Pa. , Nov. 25, 2014  Unilife Corporation ... of injectable drug delivery systems, today announced that its ... to present at the Piper Jaffray 26th Annual Healthcare ... a.m. EST on Tuesday, December 2, 2014. ... Internet as a "live" listen only Webcast. To listen, ...
(Date:11/26/2014)... RATON, Fla. , Nov. 25, 2014 /PRNewswire/ ... entered into a multi-product ANDA agreement with Pii ... ) under which Breckenridge and Pii expect ... the terms of the agreement, Pii will develop, ... market and distribute the products under its own ...
Breaking Medicine Technology:Nanomix Receives ISO 13485:2003 Certification 2Unilife to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2nd 2Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with Pharmaceutics International, Inc. 2
... Reportlinker.com announces that a new market research ... ENT Devices Market Outlook in Brazil to ... Diagnostic Devices http://www.reportlinker.com/p0259722/ENT-Devices-Market-Outlook-in-Brazil-to-2017---Hearing-Aid-Devices-and-Implants-and-Diagnostic-Devices.html ... to 2017 - Hearing Aid Devices and Implants ...
... 14, 2011 New 5-year data from the longest ... show that Neupro® (rotigotine) demonstrated continued symptomatic clinical benefit ... year period, clinically significant augmentation occurred in 5.1% of ... and 3 mg/24h) and in 13.2% of patients receiving ...
Cached Medicine Technology:Reportlinker Adds ENT Devices Market Outlook in Brazil to 2017 - Hearing Aid Devices and Implants and Diagnostic Devices 2Reportlinker Adds ENT Devices Market Outlook in Brazil to 2017 - Hearing Aid Devices and Implants and Diagnostic Devices 3Reportlinker Adds ENT Devices Market Outlook in Brazil to 2017 - Hearing Aid Devices and Implants and Diagnostic Devices 4Reportlinker Adds ENT Devices Market Outlook in Brazil to 2017 - Hearing Aid Devices and Implants and Diagnostic Devices 5Reportlinker Adds ENT Devices Market Outlook in Brazil to 2017 - Hearing Aid Devices and Implants and Diagnostic Devices 6Reportlinker Adds ENT Devices Market Outlook in Brazil to 2017 - Hearing Aid Devices and Implants and Diagnostic Devices 7Reportlinker Adds ENT Devices Market Outlook in Brazil to 2017 - Hearing Aid Devices and Implants and Diagnostic Devices 8Reportlinker Adds ENT Devices Market Outlook in Brazil to 2017 - Hearing Aid Devices and Implants and Diagnostic Devices 9Reportlinker Adds ENT Devices Market Outlook in Brazil to 2017 - Hearing Aid Devices and Implants and Diagnostic Devices 10New Data Show Low Incidence of Augmentation of Restless Legs Syndrome With 5-Year Neupro® (rotigotine) Treatment 2New Data Show Low Incidence of Augmentation of Restless Legs Syndrome With 5-Year Neupro® (rotigotine) Treatment 3New Data Show Low Incidence of Augmentation of Restless Legs Syndrome With 5-Year Neupro® (rotigotine) Treatment 4New Data Show Low Incidence of Augmentation of Restless Legs Syndrome With 5-Year Neupro® (rotigotine) Treatment 5New Data Show Low Incidence of Augmentation of Restless Legs Syndrome With 5-Year Neupro® (rotigotine) Treatment 6
(Date:11/27/2014)... (PRWEB) November 27, 2014 Blood-borne pathogens ... many medical precautions and procedures in place to counter ... and disposal of things tainted with menstrual blood are ... design a simpler, more sanitary way to handle tampons ... an inventor from Sonora, Calif. , He then created ...
(Date:11/27/2014)... 27, 2014 Nearly 1,100 Risperdal ... in a consolidated litigation now underway in Pennsylvania ... Documents recently updated in the Philadelphia Court of ... state proceeding, all of which involve a drug ... psychiatric conditions. Many of the cases in this ...
(Date:11/27/2014)... HealthDay Reporter WEDNESDAY, Nov. 26, 2014 ... safe and produces an immune system response that could protect ... results reported by the U.S. National Institutes of Health. ... vaccine paves the way for field-testing it in the Ebola-stricken ... as January, said Dr. Anthony Fauci, director of the NIH,s ...
(Date:11/27/2014)... NY (PRWEB) November 27, 2014 The founders ... offering stylish, comfortable and high functioning compression socks, are proud ... newly-released socks use an innovative Gradient Pressure (TM) knitting technology ... blood. , VIM & VIGR’s commitment to adding flair and ... as just functional recently caught the eye of a writer ...
(Date:11/27/2014)... 27, 2014 Tylenol lawsuits ( http://www.tylenollawsuitcenter.com/ ... injured by the medication are continuing to move forward ... looking ahead to a status conference in December, Bernstein ... Order issued earlier this year, a conference in the ... 10:00 a.m. Items likely to be discussed at the ...
Breaking Medicine News(10 mins):Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 2Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 3Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 4Health News:Early Trial Promising for Ebola Vaccine 2Health News:Early Trial Promising for Ebola Vaccine 3Health News:VIM & VIGR Announces Launch of Men’s Line of Compression Socks 2Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 2Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 3
... effects of the menstrual cycle on sportswomen has suggested that ... period. The// researcher Inger Jacobson connects the incidence of injuries ... hormone which relaxes ligaments) to rise during menstruation. ... seen that women who were not on birth control ...
... Cholesterol is a chemical that is made in the liver from ... present in the blood stream. Some cholesterol is needed to keep ... conditions such as angina, heart attack and strokes due to a ... of the arteries. , ,Why Use Cholestrak? , ,We are ...
... Health has indicated the current situation with both these viral infections ... reports of 9453 cases and 157 deaths as a whole ... ,In Delhi and NCR - one of the worst affected ... have been reported from Delhi, NCR and other states. There ...
... at blocking lawyers' access to a high-profile detainee at ... //techniques "national security secrets" whose revelation could "cause extremely ... said the prisoners at secret CIA prisons must not ... on them - even to their lawyers, the Post ...
... Researchers want doctors to be ready to handle medical problems ... it. //In the present state, what happens when a person ... get back to normal conditions for treatment in time simply ... findings from a UF study show there is little difference ...
... has been simmering in the trans-fat controversy for quite a ... ally- the hydrogenated// vegetable oils! This is perhaps the last ... Asda, Sainsbury’s and Tesco have already communicated their intention of ... Journal has urged the Government to bring in a law ...
Cached Medicine News:Health News:Researchers explore medicine in space 2Health News:Researchers explore medicine in space 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: